drug
ENV-6946
Phase 1updated 5mo agoby Enveda Biosciences Inc
Phase 1community read0 votes
indications
indications
IBD (Crohn's + UC)
all catalysts(0)
nothing on the calendar yet
News(3)
- AI drug hunter Enveda raises $311M for late-stage obesity, inflammatory disease pushTech darling Enveda has raised a total of $845 million in the past six years. The latest funding round is intended to pave the way for an IPO someday.biospace · 10d ago
- Enveda reaps $311M series E to feed ambition to become a ‘household name’Enveda has raised a $311 million series E round, positioning the nature-derived drug discovery company to pursue its goal of becoming a household name over the next decade.fiercebiotech · 10d ago
- Enveda’s exercise-simulating obesity tablet clears early clinical testTouting an “exceptional” gastrointestinal safety profile for its oral obesity drug candidate in a study of healthy volunteers, Enveda plans to test the asset in people stopping GLP-1 treatment.biospace · 1mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that